CASTOR: STUDY DESIGN & PATIENT CHARACTERISTICS

The CASTOR Trial: DARZALEX®+ Vd After 1 Prior MM Therapy

Share
email facebook linkedin twitter print

DARZALEX® + Velcade® (bortezomib) + dexamethasone

A multicenter, open-label, active-controlled phase 3 study1,2

  • A majority (76%) of patients received prior treatment with an immunomodulatory agent
  • More than half (69%) of patients received prior treatment with a proteasome inhibitor (PI)1

Patients were refractory to prior therapies1,2*

  • 32% to the last line of treatment
  • 33% to an immunomodulatory agent only
    • 24% in the DARZALEX® + Vd arm and 33% in the Vd arm to lenalidomide
*Please note that this is not a full list of prior therapies reported at baseline and that bortezomib-refractory patients were excluded from the study.2
 

Patient Characteristics

Baseline demographics were similar between arms1-3

ECOG=Eastern Cooperative Oncology Group.

The primary endpoint was PFS,† and the median follow-up was 7.4 months1,2

PFS=progression-free survival.

†Efficacy was evaluated by PFS based on International Myeloma Working Group criteria.1

Daratumumab (DARZALEX®) in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, is recommended by the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) as a preferred Category 1‡ therapeutic option for previously treated multiple myeloma§

‡Category 1=based upon high-level evidence, there is uniform National Comprehensive Cancer Network® (NCCN®) consensus that the intervention is appropriate.

§Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Multiple Myeloma V.2.2020. © National Comprehensive Cancer Network, Inc. 2020. All rights reserved. To view the most recent and complete version of the guideline, go online to www.nccn.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

EFFICACY – CASTOR